MY207909A - Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine - Google Patents

Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine

Info

Publication number
MY207909A
MY207909A MYPI2022002810A MYPI2022002810A MY207909A MY 207909 A MY207909 A MY 207909A MY PI2022002810 A MYPI2022002810 A MY PI2022002810A MY PI2022002810 A MYPI2022002810 A MY PI2022002810A MY 207909 A MY207909 A MY 207909A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical formulations
methylpyridin
triazin
fluorophenyl
chloro
Prior art date
Application number
MYPI2022002810A
Inventor
Corswant Christian Von
Anders Holmgren
Annika Kyss
Urban Skantze
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MY207909A publication Critical patent/MY207909A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Solid pharmaceutical formulations including AZD4635 are described. The solid formulations can include a polymeric stabilizer (e.g., a polyvinylpyrollidone), an ionic surfactant (e.g., sodium docusate), and a non-ionic surfactant (e.g., a poloxamer).
MYPI2022002810A 2019-12-02 2020-12-01 Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine MY207909A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962942417P 2019-12-02 2019-12-02
PCT/EP2020/084160 WO2021110697A1 (en) 2019-12-02 2020-12-01 Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine

Publications (1)

Publication Number Publication Date
MY207909A true MY207909A (en) 2025-03-27

Family

ID=73698812

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022002810A MY207909A (en) 2019-12-02 2020-12-01 Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine

Country Status (16)

Country Link
US (1) US12502355B2 (en)
EP (1) EP4069199B1 (en)
JP (1) JP7731883B2 (en)
KR (1) KR20220109430A (en)
CN (1) CN114727963B (en)
AR (1) AR120653A1 (en)
AU (1) AU2020395495B2 (en)
BR (1) BR112022010626A2 (en)
CA (1) CA3162154A1 (en)
ES (1) ES2977281T3 (en)
IL (1) IL293268A (en)
MX (1) MX2022006662A (en)
MY (1) MY207909A (en)
PL (1) PL4069199T3 (en)
TW (1) TWI870511B (en)
WO (1) WO2021110697A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130814A1 (en) * 2006-08-30 2013-08-08 Novartis Ag BENZIMIDAZOLYL PYRIDYL ETHER SALTS AND FORMULATIONS CONTAINING THEM
ES2579949T3 (en) * 2010-02-05 2016-08-17 Heptares Therapeutics Limited 1,2,4-triazin-4-amine derivatives
BR112012026843A2 (en) 2010-04-20 2016-07-12 Cipla Ltd composition, pharmaceutical composition, process for preparing a pharmaceutical composition, use of a composition and method for treating HIV
NZ708272A (en) * 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
MX2017011469A (en) * 2015-03-10 2018-01-23 Shionogi Inc Solid dispersions.
MX2019015885A (en) * 2017-06-22 2020-09-10 Novartis Ag Antibody molecules to cd73 and uses thereof.
WO2020065036A1 (en) * 2018-09-27 2020-04-02 Iteos Therapeutics S.A. Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist

Also Published As

Publication number Publication date
EP4069199B1 (en) 2024-01-17
AU2020395495B2 (en) 2024-05-09
IL293268A (en) 2022-07-01
WO2021110697A1 (en) 2021-06-10
US12502355B2 (en) 2025-12-23
CN114727963B (en) 2024-12-27
JP7731883B2 (en) 2025-09-01
KR20220109430A (en) 2022-08-04
CA3162154A1 (en) 2021-06-10
AU2020395495A1 (en) 2022-07-14
TWI870511B (en) 2025-01-21
US20230000775A1 (en) 2023-01-05
ES2977281T3 (en) 2024-08-21
JP2023505128A (en) 2023-02-08
EP4069199A1 (en) 2022-10-12
AR120653A1 (en) 2022-03-09
CN114727963A (en) 2022-07-08
BR112022010626A2 (en) 2022-08-16
MX2022006662A (en) 2022-07-05
TW202133859A (en) 2021-09-16
PL4069199T3 (en) 2024-06-10

Similar Documents

Publication Publication Date Title
WO2020016659A3 (en) Multiparticulate formulations of cannabinoids
CO2019003630A2 (en) Non-protein clostridial toxin compositions
WO2016149028A3 (en) Epinephrine formulations
MA52965B1 (en) GIP/GLP1 AGONIST COMPOSITIONS
EP4685160A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MY204993A (en) Formulations
UY38080A (en) LOW PH PHARMACEUTICAL FORMULATION
MX395336B (en) PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY AND ITS APPLICATION IN MEDICINE.
MX2022010831A (en) Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof.
DK1885336T3 (en) Suspension formulations comprising an active principle, a surfactant poloxamer or meroxapol agent and a glycol, as well as their use in the manufacture of a medicament for the treatment of eye disorders
AU2019339740A8 (en) CSF-1R antibody formulation
MX2021013488A (en) Liquid oral dosage formulations of methylnaltrexone.
TW201613557A (en) Stable aqueous recombinant protein formulations
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
EA202190561A1 (en) AG10 PREPARATIONS
MX2018008868A (en) Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties.
MX2020009935A (en) Stable aqueous anti-tau antibody formulations.
MX2025012462A (en) LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS
DK1906916T3 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a tonicity regulating glycol based agent, use of the composition for the manufacture of a medicament for the treatment of ophthalmic disorders
MX2025010834A (en) Formulations of an antiviral prodrug
WO2020089942A3 (en) A liquid injectable composition
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
MX2022004014A (en) Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxoh exanoate for intravenous administration and the use thereof.
MX2023002352A (en) Mcl-1 inhibitor formulations.
MY155660A (en) Novel compositons of treatment of essential thrombocythemia